A comparative study on the effects of niacin plus atorvastatin with that of fenofibrate plus atorvastatin in dyslipidemia patients
To evaluate the efficacy of fenofibrate, simvastatin or their combination in type 2 diabetic patient...
Aim: Niacin and fenofibrate are to date the most effective available HDL-C raising therapies. We exa...
extending treatment beyond statins in the high-risk cardiovascular patient Gerald F Watts,1 Fredrik ...
The study was designed to evaluate and compare the effects of co-administration of atorvastatin (10 ...
OBJECTIVES: Atherogenic dyslipidemia is emerging as a target of lipid-modifying therapy. However, an...
Diabetes is the most common metabolic disease. Type 2 diabetes is a variable combination of insulin ...
William Insull Jr1, Peter P Toth2, H Robert Superko3, Roopal B Thakkar4, Scott Krause4, Ping Jiang4,...
ObjectivesWe compared vascular and metabolic responses (and adverse responses) to statin and fibrate...
<p>Plasma total cholesterol (A), triglycerides (B) and HDL-cholesterol levels were measured at vario...
Anbu Pandian1, Anjali Arora2, Laurence S Sperling1, Bobby V Khan11Emory University School of Medicin...
6 f.Etofibrate is a hybrid drug which combines niacin with clofibrate. After contact with plasma hyd...
Jose G Jimenez-Montero,1 Gregory Haft2 1Post Graduate Studies, University of Medical Sciences, San J...
Hyperlipidemia is an important risk factor for atherosclerosis. Hemorheological factors contribute t...
The objective of the present study was to compare the effects of fenofibrate versus simvastatin on v...
Aim: Niacin and fenofibrate are to date the most effective available HDL-C raising therapies. We exa...
To evaluate the efficacy of fenofibrate, simvastatin or their combination in type 2 diabetic patient...
Aim: Niacin and fenofibrate are to date the most effective available HDL-C raising therapies. We exa...
extending treatment beyond statins in the high-risk cardiovascular patient Gerald F Watts,1 Fredrik ...
The study was designed to evaluate and compare the effects of co-administration of atorvastatin (10 ...
OBJECTIVES: Atherogenic dyslipidemia is emerging as a target of lipid-modifying therapy. However, an...
Diabetes is the most common metabolic disease. Type 2 diabetes is a variable combination of insulin ...
William Insull Jr1, Peter P Toth2, H Robert Superko3, Roopal B Thakkar4, Scott Krause4, Ping Jiang4,...
ObjectivesWe compared vascular and metabolic responses (and adverse responses) to statin and fibrate...
<p>Plasma total cholesterol (A), triglycerides (B) and HDL-cholesterol levels were measured at vario...
Anbu Pandian1, Anjali Arora2, Laurence S Sperling1, Bobby V Khan11Emory University School of Medicin...
6 f.Etofibrate is a hybrid drug which combines niacin with clofibrate. After contact with plasma hyd...
Jose G Jimenez-Montero,1 Gregory Haft2 1Post Graduate Studies, University of Medical Sciences, San J...
Hyperlipidemia is an important risk factor for atherosclerosis. Hemorheological factors contribute t...
The objective of the present study was to compare the effects of fenofibrate versus simvastatin on v...
Aim: Niacin and fenofibrate are to date the most effective available HDL-C raising therapies. We exa...
To evaluate the efficacy of fenofibrate, simvastatin or their combination in type 2 diabetic patient...
Aim: Niacin and fenofibrate are to date the most effective available HDL-C raising therapies. We exa...
extending treatment beyond statins in the high-risk cardiovascular patient Gerald F Watts,1 Fredrik ...
